Andrew Mackinnon, Executive GM, Medable, discusses how AI-driven innovations are streamlining clinical trials through ...

Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses industry’s next steps in being ...

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Leveraging artificial intelligence-powered stochastic methods for clinical data review represents a significant leap beyond ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, highlights how addressing these challenges ...

FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Andrew Mackinnon, Executive GM, Medable, explains how the company’s recent approval in France could support the expansion of ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses findings from the report and the ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

In this video interview, Cameron Breze, product manager, Inovalon, highlights current trends with decentralization and how a ...